BRAF And Related Inhibitors In Development
This article was originally published in Pharmaceutical Approvals Monthly
You may also be interested in...
Surprisingly positive data from two early-stage trials in metastatic melanoma with Plexxikon/Roche’s BRAF inhibitor, PLX-4032, and its quick move into Phase III, is garnering attention for the new class of cancer therapy. But there is one troubling sign of toxicity, and other research on the BRAF pathway is prompting debate over the pros and cons of specific versus broad activity.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011